首页 > 最新文献

Journal of clinical trials最新文献

英文 中文
Human Clinical Trials with Vaccines 疫苗的人体临床试验
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.S8.E002
P. John
{"title":"Human Clinical Trials with Vaccines","authors":"P. John","doi":"10.35248/2167-0870.20.S8.E002","DOIUrl":"https://doi.org/10.35248/2167-0870.20.S8.E002","url":null,"abstract":"","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"1 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89336191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laparoscopic Totally Extraperitoneal Repair Versus Open Prolene Hernia System For Inguinal Hernia Repair: a Clinical Trial 腹腔镜腹股沟疝全腹膜外修补与开放式Prolene疝修补:临床试验
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.10.398
S. Susmallian, O. Ponomarenko, R. Barnea
{"title":"Laparoscopic Totally Extraperitoneal Repair Versus Open Prolene Hernia System For Inguinal Hernia Repair: a Clinical Trial","authors":"S. Susmallian, O. Ponomarenko, R. Barnea","doi":"10.35248/2167-0870.20.10.398","DOIUrl":"https://doi.org/10.35248/2167-0870.20.10.398","url":null,"abstract":"","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"23 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91539877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary Causes of Skin and Soft Tissue Infections in Jamaica 当代牙买加皮肤和软组织感染的原因
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.10.399
D. Robinson, F. Pitkin, R. Whitely
Skin and soft tissue infections (SSTIs) are common clinical conditions ranging from mild superficial/cutaneous legions to life-threatening disseminated infections. Roughly 15% of the patients that seek medical intervention have a skin lesion or disease which is infectious. The emergence and rapid spread of antimicrobial resistance has complicated the therapy and negatively impacted patient outcomes in cases of SSTIs. This study serves to highlight the most common causative agents of SSTIs in Jamaica based on frequency of isolation, their drug resistance, and also their frequency associated with the different demographic groups during the time period covered. Data pertaining to culture and sensitivity of SSTIs done between 2012 and 2015 was collated from the main reference lab in Jamaica, with permission from Ministry of Health (MOH), and analyzed with the IBM SPSS 25 system. The patients included 139 females, 163 males and 75 of unknown gender. The order etiological agents causing skin and soft tissue infections in Jamaica closely mirrors the order reported in North America, Latin America and Europe with S. aureus being the most prevalent followed by various Enterobacteriaceae, P. aeruginosa and β-hemolytic Streptococci. This study showed that 77.1% of the SSTI isolates were resistant to at least one drug while 18.8% were deemed to be multidrug-resistant (MDR) and one case of extensive drug-resistance (XDR) was noted in 2012. The frequency of overall drug resistance and MDR isolates increased from 2013 to 2015. With the etiology of SSTIs in Jamaica mirroring global trends, it critical that we pay close attention to current global trends and recommendations concerning the management of SSTIs in order to improve patient outcomes.
皮肤和软组织感染(SSTIs)是常见的临床疾病,从轻微的浅表/皮肤军团到危及生命的弥散性感染。大约15%寻求医疗干预的患者有皮肤损伤或传染性疾病。抗菌素耐药性的出现和迅速蔓延使治疗复杂化,并对性传播感染患者的预后产生负面影响。这项研究的目的是根据隔离频率、耐药性以及与所涉期间不同人口群体相关的频率,重点介绍牙买加最常见的性传播感染病原体。经卫生部许可,从牙买加主要参考实验室整理了2012年至2015年期间完成的与ssti培养和敏感性有关的数据,并使用IBM SPSS 25系统进行了分析。其中女性139例,男性163例,性别不详75例。牙买加引起皮肤和软组织感染的病原顺序与北美、拉丁美洲和欧洲报告的顺序非常相似,其中金黄色葡萄球菌最为普遍,其次是各种肠杆菌科、铜绿假单胞菌和β-溶血性链球菌。本研究显示,77.1%的SSTI分离株至少对一种药物耐药,18.8%的SSTI分离株被认为是多重耐药(MDR), 2012年发现了1例广泛耐药(XDR)。2013 - 2015年总体耐药和耐多药分离株频率呈上升趋势。由于牙买加性传播感染的病因反映了全球趋势,因此我们必须密切关注当前的全球趋势和有关性传播感染管理的建议,以改善患者的预后。
{"title":"Contemporary Causes of Skin and Soft Tissue Infections in Jamaica","authors":"D. Robinson, F. Pitkin, R. Whitely","doi":"10.35248/2167-0870.20.10.399","DOIUrl":"https://doi.org/10.35248/2167-0870.20.10.399","url":null,"abstract":"Skin and soft tissue infections (SSTIs) are common clinical conditions ranging from mild superficial/cutaneous legions to life-threatening disseminated infections. Roughly 15% of the patients that seek medical intervention have a skin lesion or disease which is infectious. The emergence and rapid spread of antimicrobial resistance has complicated the therapy and negatively impacted patient outcomes in cases of SSTIs. This study serves to highlight the most common causative agents of SSTIs in Jamaica based on frequency of isolation, their drug resistance, and also their frequency associated with the different demographic groups during the time period covered. Data pertaining to culture and sensitivity of SSTIs done between 2012 and 2015 was collated from the main reference lab in Jamaica, with permission from Ministry of Health (MOH), and analyzed with the IBM SPSS 25 system. The patients included 139 females, 163 males and 75 of unknown gender. The order etiological agents causing skin and soft tissue infections in Jamaica closely mirrors the order reported in North America, Latin America and Europe with S. aureus being the most prevalent followed by various Enterobacteriaceae, P. aeruginosa and β-hemolytic Streptococci. This study showed that 77.1% of the SSTI isolates were resistant to at least one drug while 18.8% were deemed to be multidrug-resistant (MDR) and one case of extensive drug-resistance (XDR) was noted in 2012. The frequency of overall drug resistance and MDR isolates increased from 2013 to 2015. With the etiology of SSTIs in Jamaica mirroring global trends, it critical that we pay close attention to current global trends and recommendations concerning the management of SSTIs in order to improve patient outcomes.","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"61 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91024897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethical Issues for Pregnant Women with Influenza Randomized Clinical Trials 流感孕妇随机临床试验的伦理问题
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.S4.E001
M. Christian
{"title":"Ethical Issues for Pregnant Women with Influenza Randomized Clinical Trials","authors":"M. Christian","doi":"10.35248/2167-0870.20.S4.E001","DOIUrl":"https://doi.org/10.35248/2167-0870.20.S4.E001","url":null,"abstract":"","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"42 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77254221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does this Patient Really Die for Covid-19? 这个病人真的会死于Covid-19吗?
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.S3.003
G. Isaia, R. Marinello, V. Tibaldi, C. Tamone, M. Bo
This paper reports the case of a patient with a long-standing history of Alzheimer's Disease with dysphagia and total functional dependence, and a left-arm fracture one month before hospitalization with consequently bedrest.
本文报告了一例长期患有阿尔茨海默病的患者,伴有吞咽困难和完全功能依赖,住院前一个月左臂骨折,因此卧床不起。
{"title":"Does this Patient Really Die for Covid-19?","authors":"G. Isaia, R. Marinello, V. Tibaldi, C. Tamone, M. Bo","doi":"10.35248/2167-0870.20.S3.003","DOIUrl":"https://doi.org/10.35248/2167-0870.20.S3.003","url":null,"abstract":"This paper reports the case of a patient with a long-standing history of Alzheimer's Disease with dysphagia and total functional dependence, and a left-arm fracture one month before hospitalization with consequently bedrest.","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"62 1","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72702369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Convalescent Plasma as a Plausible Therapeutic Option for nCOVID-19: A Review 恢复期血浆作为一种似是而非的治疗选择:综述
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.10.409
T. Anudeep, Madhan Jeyaraman, Dharma U. Shetty, M. Hemmanthraj, Ajay Ss, Rajeswari Somasundaram, Vinodh Kumar, R. Jain, Shirodkar Jasw, I. Dilip
The world is battling a pandemic caused by the newly emerged strain of coronavirus; upon identification SARSCoV-2 and in interim named nCOVID-19 by the World Health Organization (WHO). The contagion has sparked a war against humanity with the current global toll of 1,12,241 human lives. Till date no definitive treatment against SARS-CoV-2 has been established. Similar picture of lack of licensed definitive therapy can be traced back to Ebola outbreak and the WHO directed for considering convalescent plasma (CP) therapy for its control. The history of CP as therapeutics dates back to 20th century which renders a scope for consideration in the management of nCOVID-19. Experience from prior outbreak of SARS-CoV-1 has shown that convalescent sera contain neutralizing antibodies to the relevant virus. The core principle of this passive antibody therapy is based on retrieving virus neutralizing antibodies from recovered patients with all ethical considerations and using it as prophylaxis in exposed cases or as therapy in infected patients. It is more effective as prophylaxis than as a treatment modality for the disease. However, when used in early phase of disease, the evidences have reported a decrease in mortality. Cocktails with monoclonal antibodies have also been reported beneficial, but calls for establishing pros and cons in further detail. The sole objective of this review article is to explain how and why the convalescent plasma can serve as a plausible therapeutic modality. In addition, it renders a bird’s eye view on current clinical trials for the same.
世界正在与新出现的冠状病毒引起的大流行作斗争;经鉴定为SARSCoV-2,世界卫生组织暂时将其命名为nCOVID-19。这种传染病引发了一场反人类的战争,目前全球共有112241人死亡。迄今为止,尚未确定针对SARS-CoV-2的明确治疗方法。缺乏获得许可的明确治疗方法的类似情况可追溯到埃博拉疫情,世卫组织指示考虑将恢复期血浆(CP)治疗作为其控制。CP作为治疗药物的历史可以追溯到20世纪,这为covid -19的管理提供了一个值得考虑的范围。以往SARS-CoV-1爆发的经验表明,恢复期血清中含有针对相关病毒的中和抗体。这种被动抗体治疗的核心原则是基于从康复患者中提取病毒中和抗体,并将其用作暴露病例的预防或感染患者的治疗。它作为一种预防方法比作为一种治疗方法更有效。然而,当在疾病的早期阶段使用时,有证据表明死亡率降低。单克隆抗体鸡尾酒也被报道是有益的,但需要进一步详细地确定利弊。这篇综述文章的唯一目的是解释恢复期血浆如何以及为什么可以作为一种合理的治疗方式。此外,它还提供了目前的临床试验的鸟瞰图。
{"title":"Convalescent Plasma as a Plausible Therapeutic Option for nCOVID-19: A Review","authors":"T. Anudeep, Madhan Jeyaraman, Dharma U. Shetty, M. Hemmanthraj, Ajay Ss, Rajeswari Somasundaram, Vinodh Kumar, R. Jain, Shirodkar Jasw, I. Dilip","doi":"10.35248/2167-0870.20.10.409","DOIUrl":"https://doi.org/10.35248/2167-0870.20.10.409","url":null,"abstract":"The world is battling a pandemic caused by the newly emerged strain of coronavirus; upon identification SARSCoV-2 and in interim named nCOVID-19 by the World Health Organization (WHO). The contagion has sparked a war against humanity with the current global toll of 1,12,241 human lives. Till date no definitive treatment against SARS-CoV-2 has been established. Similar picture of lack of licensed definitive therapy can be traced back to Ebola outbreak and the WHO directed for considering convalescent plasma (CP) therapy for its control. The history of CP as therapeutics dates back to 20th century which renders a scope for consideration in the management of nCOVID-19. Experience from prior outbreak of SARS-CoV-1 has shown that convalescent sera contain neutralizing antibodies to the relevant virus. The core principle of this passive antibody therapy is based on retrieving virus neutralizing antibodies from recovered patients with all ethical considerations and using it as prophylaxis in exposed cases or as therapy in infected patients. It is more effective as prophylaxis than as a treatment modality for the disease. However, when used in early phase of disease, the evidences have reported a decrease in mortality. Cocktails with monoclonal antibodies have also been reported beneficial, but calls for establishing pros and cons in further detail. The sole objective of this review article is to explain how and why the convalescent plasma can serve as a plausible therapeutic modality. In addition, it renders a bird’s eye view on current clinical trials for the same.","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"40 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86214187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Clinical Trails and Challenges 临床试验与挑战
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.S7.E001
D. Prie
{"title":"Clinical Trails and Challenges","authors":"D. Prie","doi":"10.35248/2167-0870.20.S7.E001","DOIUrl":"https://doi.org/10.35248/2167-0870.20.S7.E001","url":null,"abstract":"","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"5 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91091345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Project Management on Clinical Trials-1 临床试验研究项目管理-1
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.10.400
S. Alsuwaidan
The scenario of this project came from amalgamation of both good clinical practice (GCP) the project management for professional (PMP); since all research studies and clinical trials are considered as research project then we have to prepare and formulate a “Research Manager” for research projects with specific job description for what are the steps to follow to get a successful and completed clinical trials. In-fact, writing this book depends on two main references articles namely: “A guide to the project management body of knowledge: (PMBOK guide)” project management for professional and “Clinical Trials Requirement Guideline (version 1.3)”, Drug sector, Saudi Food and Drug Authority, Kingdom of Saudi Arabia.
这个项目的场景来自于良好临床实践(GCP)和专业项目管理(PMP)的合并;由于所有的研究和临床试验都被认为是研究项目,那么我们必须为研究项目准备和制定一个“研究经理”,并提供具体的工作描述,说明成功完成临床试验的步骤。事实上,撰写本书依赖于两篇主要参考文章,即:“项目管理知识体系指南(PMBOK指南)”专业项目管理和“临床试验要求指南(1.3版)”,沙特阿拉伯王国沙特食品和药物管理局药品部门。
{"title":"Research Project Management on Clinical Trials-1","authors":"S. Alsuwaidan","doi":"10.35248/2167-0870.20.10.400","DOIUrl":"https://doi.org/10.35248/2167-0870.20.10.400","url":null,"abstract":"The scenario of this project came from amalgamation of both good clinical practice (GCP) the project management for professional (PMP); since all research studies and clinical trials are considered as research project then we have to prepare and formulate a “Research Manager” for research projects with specific job description for what are the steps to follow to get a successful and completed clinical trials. In-fact, writing this book depends on two main references articles namely: “A guide to the project management body of knowledge: (PMBOK guide)” project management for professional and “Clinical Trials Requirement Guideline (version 1.3)”, Drug sector, Saudi Food and Drug Authority, Kingdom of Saudi Arabia.","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"321 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80238295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on Assessment of Burr-Hole Craniostomy for Chronic Subdural Hematoma: A Randomized Unblinded Comparative Trial of Burr-HoleCraniostomies and Drainage with or without Irrigation for Newly Progressed Chronic Subdural Hematoma 慢性硬膜下血肿的钻孔开颅术评价:一项随机非盲对照试验:新进展的慢性硬膜下血肿的钻孔开颅术与有或无冲洗引流
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.10.422
Sayaka Ito, Haruka Miyata, Tomoaki Fujita, Y. Nonoyama, T. Nakazawa, ShigeharuFukao
Chronic subdural hematoma (CSDH) is one of the most common clinical entities in neurosurgical practice. Although the therapeutic management is well established with burr-hole craniostomy and drainage, patients with CSDH still suffer from recurrence up to 33% [1-3]. Recently reported randomized controlled studies revealed that drainage is the most effective treatment in controlling recurrence [4,5]. As far as we know, there is no reported trials revealing whether simple drainage without irrigation (simple drainage) or with irrigation (irrigation drainage) could treat CSDH with less recurrence rate compared to the other. The purpose of this study is toanalyze thepostoperative recurrence rate and complications between drainage with and without irrigation. The present trial is permitted by Institutional Review Board of Kyoto Okamoto Memorial Hospital (No. 2020-18).
慢性硬膜下血肿(CSDH)是神经外科最常见的临床疾病之一。虽然采用钻孔开颅引流的治疗方法较为完善,但CSDH患者的复发率仍高达33%[1-3]。最近报道的随机对照研究表明,引流是控制复发最有效的治疗方法[4,5]。据我们所知,目前还没有文献报道单纯引流不灌水(simple drainage)或灌水(irrigation drainage)治疗CSDH的复发率比单纯引流低。本研究的目的是分析有冲洗和无冲洗引流的术后复发率和并发症。本试验经京都冈本纪念医院机构审查委员会(No. 2020-18)批准。
{"title":"Commentary on Assessment of Burr-Hole Craniostomy for Chronic Subdural Hematoma: A Randomized Unblinded Comparative Trial of Burr-HoleCraniostomies and Drainage with or without Irrigation for Newly Progressed Chronic Subdural Hematoma","authors":"Sayaka Ito, Haruka Miyata, Tomoaki Fujita, Y. Nonoyama, T. Nakazawa, ShigeharuFukao","doi":"10.35248/2167-0870.20.10.422","DOIUrl":"https://doi.org/10.35248/2167-0870.20.10.422","url":null,"abstract":"Chronic subdural hematoma (CSDH) is one of the most common clinical entities in neurosurgical practice. Although the therapeutic management is well established with burr-hole craniostomy and drainage, patients with CSDH still suffer from recurrence up to 33% [1-3]. Recently reported randomized controlled studies revealed that drainage is the most effective treatment in controlling recurrence [4,5]. As far as we know, there is no reported trials revealing whether simple drainage without irrigation (simple drainage) or with irrigation (irrigation drainage) could treat CSDH with less recurrence rate compared to the other. The purpose of this study is toanalyze thepostoperative recurrence rate and complications between drainage with and without irrigation. The present trial is permitted by Institutional Review Board of Kyoto Okamoto Memorial Hospital (No. 2020-18).","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"28 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88701861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malaria in Children in Guediawaye, Senegal 塞内加尔Guediawaye儿童的疟疾
Pub Date : 2020-01-01 DOI: 10.35248/2167-0870.20.10.396
A. Noubadoum, Diouf Jb, Sougou Nm, P. Adomson
Introduction: Malaria is one of the leading causes of infant and child mortality, despite the efforts made in Senegal. The objective of this study is to describe the epidemiological, clinical, Para clinical, therapeutic and evolutionary aspects of malaria in children in a pediatric ward of a Dakar hospital. Patients and methods: This is a retrospective descriptive study, with an analytical focus over a 5-year period from January 1st, 2013 to December 31st, 2017, in the pediatrics department of Roi Baudouin Hospital Center, involving 259 children hospitalized for malaria. Results: The frequency of hospitalization during the period was estimated at 7.7%.The mean age was 82.9 months, with a median of 84 months, and the age range from 1 month to 5 years was the most representative (35.9%) with extremes from 1 to 180 months. The majority of cases occurred in the last quarter of the year, with a peak in October (19.7%). Clinical manifestations on admission were dominated by fever, which was found in 93.1% of cases. More than 30.9% of the children showed clinical signs of severity on entry, with jaundice (37.5%) in the foreground, followed respectively by disturbances of consciousness (29.0%) and respiratory distress (19.0%). The majority of patients were treated with quinine (80.3%) and overall progress was satisfactory with a cure rate of 97.7%. Factors associated with death were represented by a time to management more than 7 days and the presence of co-infections, with a P. value equal to 0.002 and 0.04 respectively.
导言:尽管塞内加尔作出了努力,但疟疾仍是婴儿和儿童死亡的主要原因之一。本研究的目的是描述达喀尔医院儿科病房儿童疟疾的流行病学、临床、准临床、治疗和进化方面的情况。患者和方法:这是一项回顾性描述性研究,分析重点是2013年1月1日至2017年12月31日的5年期间,在Roi Baudouin医院中心儿科,涉及259名因疟疾住院的儿童。结果:期间住院率为7.7%。平均年龄82.9个月,中位年龄84个月,年龄以1 ~ 5岁最具代表性(35.9%),极端年龄为1 ~ 180个月。大多数病例发生在今年最后一个季度,10月为高峰(19.7%)。入院时临床表现以发热为主,占93.1%。超过30.9%的患儿在入院时表现出严重的临床症状,其中以黄疸(37.5%)最为突出,其次是意识障碍(29.0%)和呼吸窘迫(19.0%)。大多数患者接受奎宁治疗(80.3%),总体进展令人满意,治愈率为97.7%。与死亡相关的因素包括治疗时间超过7天和合并感染的存在,p值分别为0.002和0.04。
{"title":"Malaria in Children in Guediawaye, Senegal","authors":"A. Noubadoum, Diouf Jb, Sougou Nm, P. Adomson","doi":"10.35248/2167-0870.20.10.396","DOIUrl":"https://doi.org/10.35248/2167-0870.20.10.396","url":null,"abstract":"Introduction: Malaria is one of the leading causes of infant and child mortality, despite the efforts made in Senegal. The objective of this study is to describe the epidemiological, clinical, Para clinical, therapeutic and evolutionary aspects of malaria in children in a pediatric ward of a Dakar hospital. Patients and methods: This is a retrospective descriptive study, with an analytical focus over a 5-year period from January 1st, 2013 to December 31st, 2017, in the pediatrics department of Roi Baudouin Hospital Center, involving 259 children hospitalized for malaria. Results: The frequency of hospitalization during the period was estimated at 7.7%.The mean age was 82.9 months, with a median of 84 months, and the age range from 1 month to 5 years was the most representative (35.9%) with extremes from 1 to 180 months. The majority of cases occurred in the last quarter of the year, with a peak in October (19.7%). Clinical manifestations on admission were dominated by fever, which was found in 93.1% of cases. More than 30.9% of the children showed clinical signs of severity on entry, with jaundice (37.5%) in the foreground, followed respectively by disturbances of consciousness (29.0%) and respiratory distress (19.0%). The majority of patients were treated with quinine (80.3%) and overall progress was satisfactory with a cure rate of 97.7%. Factors associated with death were represented by a time to management more than 7 days and the presence of co-infections, with a P. value equal to 0.002 and 0.04 respectively.","PeriodicalId":15375,"journal":{"name":"Journal of clinical trials","volume":"48 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86737124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of clinical trials
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1